AOD-9604 is unusual: somebody ran the trial. A 24-week placebo-controlled study in about 500 people measured exactly what these photos claim, and it did not beat placebo.
AOD-9604 is a 16-amino-acid fragment of human growth hormone. The mouse data were good. Early human trials looked promising too. Then came the definitive one: 24 weeks, placebo-controlled, about 500 people, with diet and exercise added to both arms. The compound stopped separating from placebo. Development ended there. For scale, tirzepatide reached 22.5% body-weight reduction in Phase III.
The trial that measured it
AOD-9604 was built in the 1990s from the C-terminal fragment of human growth hormone, residues 176 to 191. The idea was elegant: keep the lipolytic signal, drop the growth-promoting part of the parent hormone.
It worked in rodents. Obese mice given the fragment lost fat. That result is real and it is why the compound exists.
Then it went into people. A 24-week, placebo-controlled Phase IIb trial enrolled about 500 participants — 502 in the published account — and the compound did not separate from placebo. Development stopped there.
Effects of AOD9604 on weight loss were seen in initial trials but were not seen in the last study in which an intensive diet and exercise regime was incorporated.
Moré & Kenley, Journal of Endocrinology and Metabolism, 2014That sentence is the whole story in one line, and it is more interesting than a flat failure. Early trials did show weight loss. The definitive one added an intensive diet and exercise program to both arms — and once everyone was dieting and training, the compound stopped separating from placebo.
That is the before and after. It has a control arm, a duration, and a sample size, which is more than almost anything else in this catalog can say. It is also negative. The AOD-9604 complete guide covers the full development history.
Six human trials, and none by the route it is sold for
The human record is larger than most peptides here, which makes the gap in it more striking.
- Two intravenous studies, at 25 to 400 µg/kg.
- Four oral studies, running from 54 mg a day down to 0.25 mg.
- Zero subcutaneous studies. We found no published trial of AOD-9604 injected under the skin, which is how the research market sells it.
So even the negative result was generated by routes nobody buying a vial is using. The AOD-9604 dosage page sets out what each trial administered.
What the photos are competing against
Fat-loss before-and-afters are the most saturated image category in this market, and the honest way to read one is against what the drugs that do work actually produced in trials.
| Compound | Trial | Body-weight change |
|---|---|---|
| Tirzepatide | Phase III SURMOUNT-1 | 22.5% |
| Retatrutide | Phase II | 24.2% |
| Semaglutide | Phase III STEP-1 | 14.9% |
| AOD-9604 | Phase IIb, 24 weeks | No separation from placebo |
A photograph showing a change on the scale of the top three rows, produced by the bottom row, is describing something other than the compound.
AOD-9604
The growth-hormone fragment discussed here, supplied as a research compound with a batch-matched certificate of analysis.
The GRAS label does not mean what the marketing implies
AOD-9604 is often sold alongside a claim of "GRAS" status, and readers reasonably hear that as a regulator signing off.
GRAS is a food-ingredient designation. It is not drug approval, it is not an efficacy finding, and it says nothing about the trial that failed. The FDA has never approved AOD-9604 as a drug.
AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world.
World Anti-Doping Agency statement, 2013Worth knowing separately: it has been examined in the anti-doping literature, and the compound’s status there is its own question. Are peptides legal covers the regulatory framing this market operates in.
How to read an AOD-9604 before-and-after
This compound is a useful test case, because the counterfactual actually exists.
- Ask what else changed. Most people starting a fat-loss compound also change diet and training in the same week. The trial controlled for that. A photo cannot.
- Check the route. Nothing published tested subcutaneous injection, so a subcutaneous result has no trial to sit against at all.
- Check the duration. The trial ran 24 weeks. A four-week photo is not measuring the same thing.
- Remember the direction of the finding. This is not an absence of evidence. It is evidence of absence, from a controlled study.
For contrast, tesamorelin is the same class of question answered positively: a CT scan, a randomized trial, 412 adults, and a real but modest change. That is what a working GH-axis compound looks like on paper.
AOD-9604
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- The definitive trial was negative. A 24-week placebo-controlled Phase IIb in roughly 500 participants did not separate from placebo once diet and exercise were added to both arms.
- Earlier, smaller trials did show weight loss. The effect disappeared when everyone in the study was dieting and training, which is the comparison that matters.
- Six human trials ran: two intravenous at 25–400 µg/kg, four oral. Zero tested subcutaneous injection, the route it is sold for.
- "GRAS" is a food-ingredient designation, not drug approval and not an efficacy finding.
- For scale, tirzepatide reached 22.5% body-weight reduction in Phase III. AOD-9604 reached placebo.
What we're watching
Nothing is in development, which is the most informative fact available. A compound with positive rodent data and a failed Phase IIb usually stops, and this one did. The only thing that would reopen the question is a subcutaneous trial, since that route has never been tested and is the one the research market actually uses. Nobody has announced one, and there is no commercial reason to run it.
Frequently asked questions
Does AOD-9604 actually work for fat loss?
Not once diet and exercise are controlled for. Early trials showed weight loss, but the definitive 24-week placebo-controlled study in roughly 500 participants added an intensive diet and exercise program to both arms, and the compound stopped separating from placebo. Development ended there.
How long does AOD-9604 take to work?
The failed trial ran 24 weeks, which is long enough to detect a real fat-loss effect. Photographs taken after a few weeks are not measuring the same thing the trial measured.
Is AOD-9604 FDA approved?
No. It has never been approved as a drug. The "GRAS" designation that appears in marketing is a food-ingredient classification and carries no efficacy or drug-safety finding.
Was AOD-9604 ever tested as an injection under the skin?
We found no published trial of subcutaneous AOD-9604. The human studies used intravenous and oral routes. That gap matters, because subcutaneous injection is how the research market sells it.
Why do people still report results?
Because most people starting a fat-loss compound change diet and training at the same time, and because an uncontrolled personal result has nothing to compare itself against. The trial had a placebo arm precisely to separate those.
References
- Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278. https://doi.org/10.1159/000053183
- Heffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., & Ng, F. M. (2001). The effect of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/endo.142.12.8522
- Moré, M. I., & Kenley, D. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism, 4(3), 64–77. https://doi.org/10.14740/jem213w
- Stier, H., Vos, E., & Kenley, D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1–2), 7–15. https://doi.org/10.4021/jem157w
- World Anti-Doping Agency. (2013, April 22). WADA statement on the substance AOD-9604. https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604
- Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., & Ng, F. M. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 54(3), 105–111. https://doi.org/10.1159/000053183
- Ng, F. M., Sun, J., Sharma, L., Libinaki, R., Jiang, W. J., & Gianello, R. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/en.142.12.5182
- The orally active peptide AOD 9604 may aid weight reduction in obese subjects. (2005). Inpharma Weekly, 1469, 22. https://doi.org/10.2165/00128413-200514690-00010
- Brennan, T. C., Rizzoli, R., & Ammann, P. (2009). Does the growth hormone-derived peptide AOD9604 have an anabolic effect on bone? Bone, 44(Suppl. 2), S326. https://doi.org/10.1016/j.bone.2009.03.047